Overview

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

Status:
RECRUITING

Trial end date:
2029-11-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).

Phase:

PHASE3

Details

Lead Sponsor:

Hoffmann-La Roche

Collaborator:

Chugai Pharmaceutical

Treatments:

adagrasib
sotorasib